SCHEMBL4817852

SCHEMBL4817852

Cc1ccc(O[Sc])c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.46
TDP1 Q9NUW8 2/20 0.42
TP53 P04637 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
L3MBTL1 Q9Y468 5/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 2/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4821755 0.80 ACHE (0.46) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL6035271 0.79 ACHE (0.50) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL4950654 0.79 HTR1A (0.50) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL31666386 0.79 HTR1A (0.50) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL8858967 0.78 ACHE (0.44) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL144308 0.77 ACHE (0.68) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL29352952 0.77 ACHE (0.68) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL10165952 0.75 ACHE (0.46) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL1044925 0.75 ACHE (0.46) ACHETDP1TP53ALDH1A1CYP3A4
SCHEMBL18377117 0.75 ALDH1A1 (0.46) ACHETDP1TP53ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337536-B1 CATIONIC GROUP-3 CATALYST SYSTEM EXXONMOBIL CHEM PATENTS INC (US) 2012-09-12 EP disclosed
US-7390861-B2 Cationic group-3 catalyst system EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-06-24 US disclosed
US-20040033891-A1 Cationic group-3 catalyst system EXXONMOBIL CHEMICAL PATENTS INC. 2004-02-19 US disclosed
EP-1337536-A1 CATIONIC GROUP-3 CATALYST SYSTEM ExxonMobil Chemical Patents Inc. (US) 2003-08-27 EP disclosed
WO-2002032909-A1 CATIONIC GROUP-3 CATALYST SYSTEM EXXONMOBIL CHEMICAL PATENTS INC. (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033891-A1 Cationic group-3 catalyst system COG3, ORC3, LIG3 ACHE 2631/4885TDP1 4378/4885TP53 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.